Efficacy and Safety of Ranibizumab 0.5 vs Veteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Condition:   Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
Interventions:   Drug: Ranibizumab 0.5mg;   Drug: Rranibizumab 0.5 mg;   Drug: Verteporfin PDT
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting – verified September 2013

Leave a Reply

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

  

  

  

three × three =